Trial Profile
A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Jul 2023
Price :
$35
*
At a glance
- Drugs Venetoclax (Primary) ; Azacitidine; Cyclophosphamide; Cytarabine; Decitabine; Dexamethasone; Etoposide; Pegaspargase; Protein tyrosine kinase inhibitors; Rituximab; Topotecan; Vincristine
- Indications Acute myeloid leukaemia; Cancer; Gastrointestinal stromal tumours; Neuroblastoma; Non-Hodgkin's lymphoma; Paraganglioma; Precursor cell lymphoblastic leukaemia-lymphoma; Rhabdomyosarcoma; Sarcoma; Solid tumours; Wilms' tumour
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie; AbbVie Germany
- 19 May 2023 Status changed from active, no longer recruiting to completed.
- 04 Nov 2022 Status changed from recruiting to active, no longer recruiting.
- 21 Jul 2022 Planned primary completion date changed from 25 Jul 2022 to 2 Jun 2023.